Drug Trial Radar · NCT07590531
AMT-116 in Combination With AK112 in Patients With Lung Cancer
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
118
Planned (sponsor's estimate)
Start
Jun 29, 2026
Primary completion
May 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Multitude Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- May 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of AMT-116 in combination with Ivonescimab (AK112) in patients with advanced non-small cell lung cancer (NSCLC). The study is divided into two parts: the part I is dose escalation and the Part Ⅱ for expansion.
Conditions
- Advanced Non-small Cell Lung Cancer (NSCLC)
Interventions
AMT-116Drug
AMT-116 is an antibody Drug Conjugate (ADC)
AK112Drug
AK112 is a PD-1/VEGF bispecific tumor immunotherapy drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: To evaluate the safety and tolerability of the combination of AMT-116 and AK112 in patients with advanced NSCLC and to determine the recommended Phase 2 dose (RP2CD)Time frame: approximately 10 months
- Phase I: Type, incidence and severity of Adverse Events,Dose Limiting Toxicities (DLTs)Time frame: approximately 10 months
- Phase II: Objective Response Rate(ORR)Time frame: approximately 12 months
- Phase II: Type, incidence and severity of Adverse EventsTime frame: approximately 12 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Not yet recruiting
Zhejiang cancer hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.